- Home
- ASMB vs AARD Comparison
ASMB vs AARD Comparison
Compare ASMB & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- AARD
- Stock Information
- Founded
- ASMB 2005
- AARD 2017
- Country
- ASMB United States
- AARD United States
- Employees
- ASMB N/A
- AARD N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- ASMB Health Care
- AARD Health Care
- Exchange
- ASMB Nasdaq
- AARD Nasdaq
- Market Cap
- ASMB 141.8M
- AARD 154.9M
- IPO Year
- ASMB 2010
- AARD 2025
- Fundamental
- Price
- ASMB $18.86
- AARD $12.55
- Analyst Decision
- ASMB Strong Buy
- AARD Strong Buy
- Analyst Count
- ASMB 3
- AARD 5
- Target Price
- ASMB $33.00
- AARD $33.00
- AVG Volume (30 Days)
- ASMB 29.0K
- AARD 36.9K
- Earning Date
- ASMB 08-15-2025
- AARD 08-14-2025
- Dividend Yield
- ASMB N/A
- AARD N/A
- EPS Growth
- ASMB N/A
- AARD N/A
- EPS
- ASMB N/A
- AARD N/A
- Revenue
- ASMB $32,154,000.00
- AARD N/A
- Revenue This Year
- ASMB $0.04
- AARD N/A
- Revenue Next Year
- ASMB N/A
- AARD N/A
- P/E Ratio
- ASMB N/A
- AARD N/A
- Revenue Growth
- ASMB 148.33
- AARD N/A
- 52 Week Low
- ASMB $7.75
- AARD $4.88
- 52 Week High
- ASMB $19.93
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- ASMB 55.48
- AARD N/A
- Support Level
- ASMB $16.90
- AARD N/A
- Resistance Level
- ASMB $19.43
- AARD N/A
- Average True Range (ATR)
- ASMB 1.05
- AARD 0.00
- MACD
- ASMB -0.09
- AARD 0.00
- Stochastic Oscillator
- ASMB 75.38
- AARD 0.00
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.